These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36394112)

  • 21. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 vaccine development and a potential nanomaterial path forward.
    Shin MD; Shukla S; Chung YH; Beiss V; Chan SK; Ortega-Rivera OA; Wirth DM; Chen A; Sack M; Pokorski JK; Steinmetz NF
    Nat Nanotechnol; 2020 Aug; 15(8):646-655. PubMed ID: 32669664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 vaccines: Knowing the unknown.
    Lv H; Wu NC; Mok CKP
    Eur J Immunol; 2020 Jul; 50(7):939-943. PubMed ID: 32437587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.
    Bostanghadiri N; Ziaeefar P; Mofrad MG; Yousefzadeh P; Hashemi A; Darban-Sarokhalil D
    Biomed Res Int; 2023; 2023():1879554. PubMed ID: 37674935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19.
    Mustajab T; Kwamboka MS; Choi DA; Kang DW; Kim J; Han KR; Han Y; Lee S; Song D; Chwae YJ
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of approved COVID-19 vaccines.
    Jamkhande A; Khairnar MR; Gavali N; Patil Y; Kapare SS; Bhosale KP
    Rocz Panstw Zakl Hig; 2021; 72(3):245-252. PubMed ID: 34553878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?
    Hanney SR; Wooding S; Sussex J; Grant J
    Health Res Policy Syst; 2020 Jun; 18(1):61. PubMed ID: 32513202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast.
    Inchingolo AD; Malcangi G; Ceci S; Patano A; Corriero A; Vimercati L; Azzollini D; Marinelli G; Coloccia G; Piras F; Barile G; Settanni V; Mancini A; De Leonardis N; Garofoli G; Palmieri G; Isacco CG; Rapone B; Scardapane A; Curatoli L; Quaranta N; Ribezzi M; Massaro M; Jones M; Bordea IR; Tartaglia GM; Scarano A; Lorusso F; Macchia L; Larocca AMV; Aityan SK; Tafuri S; Stefanizzi P; Migliore G; Brienza N; Dipalma G; Favia G; Inchingolo F
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The COVID-19 vaccine development: A pandemic paradigm.
    Carneiro DC; Sousa JD; Monteiro-Cunha JP
    Virus Res; 2021 Aug; 301():198454. PubMed ID: 34015363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
    Gudadappanavar AM; Benni J
    J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy.
    Ameratunga R
    Expert Rev Vaccines; 2022 Sep; 21(9):1177-1184. PubMed ID: 35695410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
    Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
    Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
    Chauhan N; Soni S; Gupta A; Aslam M; Jain U
    J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
    Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19: Clinical status of vaccine development to date.
    Kumar S; Basu M; Ghosh P; Ansari A; Ghosh MK
    Br J Clin Pharmacol; 2023 Jan; 89(1):114-149. PubMed ID: 36184710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.
    Teo SP
    J Pharm Pract; 2022 Dec; 35(6):947-951. PubMed ID: 33840294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [At least 68 vaccine candidates under development].
    Leach S
    Lakartidningen; 2020 Apr; 117():. PubMed ID: 32293018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.